Traders assign an 81% implied probability to no Encore Medical IPO before June 2026 primarily because the company’s September 2025 S-1 filing and December 2025 terms—proposing a $15 million raise at $5 per share for an expected post-IPO market capitalization near $49 million—remain unchanged without subsequent SEC updates or launch confirmations. Ongoing FDA clinical trials for its transcatheter cardiac implants continue to extend the regulatory pathway, keeping the timeline uncertain despite the NYSE American listing application. This lack of fresh catalysts, combined with the firm’s pre-revenue status and modest valuation targets, sustains trader consensus around potential delays, while the low single-digit odds on specific closing market-cap bands reflect the narrow range of outcomes if the deal proceeds promptly.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоNo IPO before June 2026 81%
55M+ 7.0%
45M–50M 7%
50M–55M 4.3%
$24,068 Обс.
$24,068 Обс.
Apr 22, 2026
<45M
3%
45M–50M
7%
50M–55M
4%
55M+
7%
No IPO before June 2026
81%
No IPO before June 2026 81%
55M+ 7.0%
45M–50M 7%
50M–55M 4.3%
$24,068 Обс.
$24,068 Обс.
Apr 22, 2026
<45M
$7,323 Обс.
3%
45M–50M
$2,625 Обс.
7%
50M–55M
$1,823 Обс.
4%
55M+
$3,121 Обс.
7%
No IPO before June 2026
$9,175 Обс.
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Traders assign an 81% implied probability to no Encore Medical IPO before June 2026 primarily because the company’s September 2025 S-1 filing and December 2025 terms—proposing a $15 million raise at $5 per share for an expected post-IPO market capitalization near $49 million—remain unchanged without subsequent SEC updates or launch confirmations. Ongoing FDA clinical trials for its transcatheter cardiac implants continue to extend the regulatory pathway, keeping the timeline uncertain despite the NYSE American listing application. This lack of fresh catalysts, combined with the firm’s pre-revenue status and modest valuation targets, sustains trader consensus around potential delays, while the low single-digit odds on specific closing market-cap bands reflect the narrow range of outcomes if the deal proceeds promptly.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Ринок відкрито: Apr 3, 2026, 7:59 PM ET
Обсяг
$24,068Дата завершення
Apr 22, 2026Ринок відкрито
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Traders assign an 81% implied probability to no Encore Medical IPO before June 2026 primarily because the company’s September 2025 S-1 filing and December 2025 terms—proposing a $15 million raise at $5 per share for an expected post-IPO market capitalization near $49 million—remain unchanged without subsequent SEC updates or launch confirmations. Ongoing FDA clinical trials for its transcatheter cardiac implants continue to extend the regulatory pathway, keeping the timeline uncertain despite the NYSE American listing application. This lack of fresh catalysts, combined with the firm’s pre-revenue status and modest valuation targets, sustains trader consensus around potential delays, while the low single-digit odds on specific closing market-cap bands reflect the narrow range of outcomes if the deal proceeds promptly.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Обсяг
$24,068Дата завершення
Apr 22, 2026Ринок відкрито
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Traders assign an 81% implied probability to no Encore Medical IPO before June 2026 primarily because the company’s September 2025 S-1 filing and December 2025 terms—proposing a $15 million raise at $5 per share for an expected post-IPO market capitalization near $49 million—remain unchanged without subsequent SEC updates or launch confirmations. Ongoing FDA clinical trials for its transcatheter cardiac implants continue to extend the regulatory pathway, keeping the timeline uncertain despite the NYSE American listing application. This lack of fresh catalysts, combined with the firm’s pre-revenue status and modest valuation targets, sustains trader consensus around potential delays, while the low single-digit odds on specific closing market-cap bands reflect the narrow range of outcomes if the deal proceeds promptly.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання